NTS071

Nutshell Therapeutics (Shanghai) Co., LTD. · Phase 1 active Small molecule

At a glance

Generic name	NTS071
Sponsor	Nutshell Therapeutics (Shanghai) Co., LTD.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NTS071 CI brief — competitive landscape report
NTS071 updates RSS · CI watch RSS
Nutshell Therapeutics (Shanghai) Co., LTD. portfolio CI